

**Riferimenti bibliografici forniti al Consiglio Superiore di Sanità  
dalla SIGO (Società Italiana Ginecologi e Ostetrici)  
a supporto del parere favorevole sull'uso della Ru 486:**

1. American College Obstetricians Gynecologists (ACOG). Practical bulletin 143, 2014 <https://www.acog.org/clinical/clinical-guidance/practice-bulletin/articles/2014/03/medical-management-of-first-trimester-abortion>
2. Royal College Obstetricians Gynecologists (RCOG). Guidelines 2011 Update guidelines 2 march 2020 <https://www.rcog.org.uk/en/guidelines-research-services/guidelines/green-top-guidelines-in-bjog/>
3. NICE. Abortion care 2019 <https://www.nice.org.uk/guidance/ng140/chapter/Recommendations>
4. HAS -CNGOF Reponses rapides dans le cadre du Covid-19 – Interruption volontaire de Grossesse avril 2020 <http://www.cngof.fr/coronavirus-go-cngof?folder=CONTRACEPTION%2B-%2BIVG%2B-%2BCOVID>
5. Ireland Health Service <https://www2.hse.ie/unplanned-pregnancy/>
6. WHO “Safe abortion: technical and policy guidance for health systems” second edition, 2012
7. WHO Task Force on Post-ovulatory Methods of Fertility Regulation. Comparison of two doses of mifepristone in combination with misoprostol for early medical abortion: a randomised trial. British Journal of Obstetrics and Gynaecology 2000;107:524–530.
8. Cioffi A, Cioffi F, Rinaldi R. COVID-19 and abortion: The importance of guaranteeing a fundamental right. Sex Reprod Healthc. 2020 Jun 6;25:100538. doi: 10.1016/j.srhc.2020.100538. Epub ahead of print. PMID: 32534228.
9. Deb S, Subasinghe AK, Mazza D. Providing medical abortion in general practice: General practitioner insights and tips for future providers. Aust J Gen Pract. 2020 Jun;49(6):331-337. doi: 10.31128/AJGP-01-20-5198. PMID: 32464728.
10. Lee S, Hitt WC. Clinical Applications of Telemedicine in Gynecology and Women's Health. Obstet Gynecol Clin North Am. 2020 Jun;47(2):259-270. doi: 10.1016/j.ogc.2020.02.002. PMID: 32451017.
11. Dzuba IG, Castillo PW, Bousiéguéz M, Margarita Lugo Hernández E, Juan Castañeda Vivar J, Sanhueza Smith P. A repeat dose of misoprostol 800mcg following mifepristone for outpatient medical abortion at 64-70 and 71-77 days of gestation: A retrospective chart review. Contraception. 2020 May 28:S0010-7824(20)30160-8. doi: 10.1016/j.contraception.2020.05.012. Epub ahead of print. PMID: 32474060.
12. Shochet T, Lerma K, Blum J, Winikoff B, Blumenthal PD. Multi-level pregnancy test use for medical abortion follow-up after 63 days' gestation: Evidence from prenatal hCG data. Contraception. 2020 May 26:S0010-7824(20)30156-6. doi: 10.1016/j.contraception.2020.05.008. Epub ahead of print. PMID: 32470467.

13. Parsons JA. 2017-19 governmental decisions to allow home use of misoprostol or early medical abortion in the UK. *Health Policy*. 2020 Jul;124(7):679-683. doi: 10.1016/j.healthpol.2020.04.014. Epub 2020 May 23. PMID: 32487442.
14. Kemppainen V, Mentula M, Palkama V, Heikinheimo O. Pain during medical abortion in early pregnancy in teenage and adult women. *Acta Obstet Gynecol Scand*. 2020 May 22. doi: 10.1111/aogs.13920. Epub ahead of print. PMID: 32441319.
15. Perreira KM, Johnston EM, Shartz A, Yin S. Perceived Access to Abortion Among Women in the United States in 2018: Variation by State Abortion Policy. *Context. Am J Public Health*. 2020 Jul;110(7):1039-1045. Doi 10.2105/AJPH.2020.305659. Epub 2020 May 21. PMID: 32437276.
16. Alam B, Kaler A, Mumtaz Z. Women's voices and medical abortions: A review of the literature. *Eur J Obstet Gynecol Reprod Biol*. 2020 Jun;249:21-31. doi: 10.1016/j.ejogrb.2020.04.003. Epub 2020 Apr 8. PMID: 32348948.
17. Gambir K, Kim C, Necastro KA, Ganatra B, Ngo TD. Self-administered versus provider-administered medical abortion. *Cochrane Database Syst Rev*. 2020 Mar 9;3(3):CD013181. doi: 10.1002/14651858.CD013181.pub2. PMID: 32150279; PMCID: PMC7062143.
18. Schmidt-Hansen M, Lord J, Hasler E, Cameron S. Simultaneous compared to interval administration of mifepristone and misoprostol for medical abortion up to 10<sup><sup>+0</sup></sup> weeks' gestation: a systematic review with meta-analyses. *BMJ Sex Reprod Health*. 2020 Feb 20;bmjsrh-2019-200448. doi: 10.1136/bmjsrh-2019-200448. Epub ahead of print. PMID: 32079651.
19. Fiala C, Bombas T, Parachini M, Agostini A, Lertxundi R, Lubusky M, Saya L, Danielsson KG. Management of very early medical abortion-An international survey among providers. *Eur J Obstet Gynecol Reprod Biol*. 2020 Mar;246:169-176. doi: 10.1016/j.ejogrb.2020.01.022. Epub 2020 Feb 1. PMID: 32035281.
20. Dzuba IG, Chong E, Hannum C, Lichtenberg ES, Lugo Hernández EM, Ngoc NTN, Patel A, Rzayeva G, Sanhueza Smith P, Tsertsvadze G, Winikoff B. A non-inferiority study of outpatient mifepristone-misoprostol medical abortion at 64-70 days and 71-77 days of gestation. *Contraception*. 2020 May;101(5):302-308. doi: 10.1016/j.contraception.2020.01.009. Epub 2020 Feb 1. PMID: 32014520.
21. DeNicola N, Grossman D, Marko K, Sonalkar S, Butler Tobah YS, Ganju N, Witkop CT, Henderson JT, Butler JL, Lowery C. Telehealth Interventions to Improve Obstetric and Gynecologic Health Outcomes: A Systematic Review. *Obstet Gynecol*. 2020 Feb;135(2):371-382. doi: 10.1097/AOG.0000000000003646. PMID: 31977782; PMCID: PMC7012339.
22. Dineley B, Munro S, Norman WV. Leadership for success in transforming medical abortion policy in Canada. *PLoS One*. 2020 Jan 8;15(1):e0227216. doi: 10.1371/journal.pone.0227216. PMID: 31914156; PMCID: PMC6948737.